VistaGen Therapeutics, Inc. (VTGN) Financials

VTGN Assets vs Liabilities
DateAssetsLiabilities
Dec. 31, 2025 65.1 million 14.1 million
Sept. 30, 2025 80.9 million 14.6 million
June 30, 2025 68.9 million 12.2 million
March 31, 2025 84.3 million 14.0 million

VTGN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2025 -17.6 million 1.1 million
Sept. 30, 2025 -13.8 million 1.1 million
June 30, 2025 -18.8 million 916000
March 31, 2025 -10.2 million 963000

VTGN Net Income

No data available :(

VTGN Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2025 61.8 million 862000 1.0 million
Sept. 30, 2025 77.2 million 610000 1.2 million
June 30, 2025 63.2 million 783000 1.4 million
March 31, 2025 80.5 million 948000 1.5 million

VTGN Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Dec. 31, 2025 42.2 million
Sept. 30, 2025 35.7 million
June 30, 2025 31.9 million
March 31, 2025 30.7 million

VTGN Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2025 60000 14.2 million 5.5 million -
Sept. 30, 2025 60000 15.9 million 4.4 million -
June 30, 2025 65000 11.7 million 4.4 million -
March 31, 2025 88000 10.2 million 4.3 million -

VTGN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2025 303000 189000
Sept. 30, 2025 258000 -
June 30, 2025 244000 169000
March 31, 2025 -15000 161000

VTGN Revenue by Segment
Graph available only for paid members. Upgrade to see it.

VTGN

Price: $0.58

52 week price:
0.43
5.14

Payout Ratio Range:
-29421.13%
-4.03%

Earnings Per Share: -1.90 USD

P/E Ratio: -0.33

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 11.3 million

Ebitda: -2.8 million

Market Capitalization: 18.4 million

Links: